Skip to main content
SpringerLink
Log in

Poliovirus combined immunization with inactivated and live attenuated vaccines

  • Chapter
Measles and Poliomyelitis

  • 163 Accesses

Summary

Since the introduction of inactivated poliovirus vaccine in 1955 and live oral poliovirus vaccine in 1962, the number of cases of paralytic poliomyelitis has declined dramatically. In the United States, approximately five cases of poliomyelitis are reported annually and all of them are vaccine-associated. World-wide, there are approximately 200000 cases of natural poliomyelitis. Both the inactivated and live vaccines have proven to be highly effective. The disadvantages of inactivated vaccine are relatively poor mucosal immunity and a belief that booster doses are required to maintain immunity. Live oral vaccine, on the other hand, is associated with paralytic poliomyelitis and poor seroconversion rates in underdeveloped regions of the world. A new enhanced potency inactivated vaccine is more immunogenic, induces greater mucosal immunity, and requires less frequent boosting than earlier inactivated preparations. A sequentional immunization schedule consisting of two doses of enhanced potency inactivated vaccine followed by two doses of the live oral vaccine has been shown to induce excellent systemic and local immunity that is long lasting. The introduction of sequentional immunization as the schedule of choice will require additional simplification of a currently complex vaccine program for polio.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (Canada)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Adenyi-Jones SC, Faden H, Ferdon MB, Kwong MS, Ogra PL (1992) Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 120: 686–689

    Article  PubMed  CAS  Google Scholar 

  2. AndrusJK, de Quadros CA, Olive JM (1992) The Surveillance Challenge: Final Stages of Eradication of Poliomyelitis in the Americas, MMWR 41/no. SS-1: 21–26

    Google Scholar 

  3. Bodian D, Nathanson N (1960) Inhibitory effects of passive antibody on virulent poliovirus excretion and on immune response in chimpanzees. Bull Johns Hopkins Hosp 107: 143–162

    PubMed  CAS  Google Scholar 

  4. Bottiger M (1987) A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 19: 595–601

    Article  PubMed  CAS  Google Scholar 

  5. Christodoulose C, Colbere-Garapin G, Macadam A (1990) Mapping of mutations asso ciated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64: 4922–4929

    Google Scholar 

  6. Dhar R, Ogra PL (1985) Local immune responses. Br Med Bull 41: 28–33

    PubMed  CAS  Google Scholar 

  7. Dick GWA, Dane DS, McAlister J, Briggs M, Nelson R, Field CMB (1961) Vaccination against poliomyelitis with live virus vaccines. Brit Med J 266–269

    Google Scholar 

  8. Domok L, Balayna MS, Fayinka OA, Skrtic N, Soneji AD, Harland PSEG (xxx) Factors affecting the efficacy of live poliovirus vaccine in warm climate. Bull WHO 51: 333–347

    Google Scholar 

  9. Expanded Programme on Immunization. Poliomyelitis in 1986, 1987 and 1988 (Part 1). (1989) Wkly Epidemiol Record 64: 273–279

    Google Scholar 

  10. Expanded Programme on Immunization. Poliomyelitis in 1986, 1987 and 1988 (Part 2). (1989) Wkly Epidemiol Record 37: 281–285

    Google Scholar 

  11. Faden H, Duffy L. (1992) Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines AJDC 146: 1320–1323

    PubMed  CAS  Google Scholar 

  12. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. J Infect Dis 162: 1291–1297

    Article  PubMed  CAS  Google Scholar 

  13. Ghendon YZ, Sanakoyeva LL (1961) Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin’s strains) in persons after naturally and experimentally acquired immunity. Acta Virol 5: 265–273

    Google Scholar 

  14. Glezen WP, Lamb GA, Beiden EA, Chin TDY (1966) Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 83:224–237

    PubMed  CAS  Google Scholar 

  15. Grenier B, Hamza B, Xueref BC, Viarme F, Roumaintzeff M (1984) Seroimmunity following vaccination in infants by an inactivated poliovirus vaccine prepared on vero cells. Rev Infect Dis 6: S545-547

    Google Scholar 

  16. HenryJL, Jaikaran ES (1966) A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg Camb 64: 105–120

    Article  PubMed  CAS  Google Scholar 

  17. Horstmann DM, Opton EM, Klemperen R, Llado B, Vignic AJ (1964) Viremia in infants vaccinated with oral poliovirus vaccine (Sabin). Am J Hygiene 79:47–63

    CAS  Google Scholar 

  18. Hovi T, Huovilainen A, Kuronen T, Poyry T, Salama N, Cantell K, Kinnunen E, Lapinleimu K, Roivainen M, Stenvik M (1986) Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. The Lancet II: 1427–1432

    Article  Google Scholar 

  19. John TJ, Christopher S (1975) Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take, and antibody response. Am J Epidemiol 102: 422–428

    PubMed  CAS  Google Scholar 

  20. Kohara M, Abe S, Kamatsu T, Tago K, Arita M, Nomoto A (1988) A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. J Virol 62: 2828–2835

    PubMed  CAS  Google Scholar 

  21. Lasch EE, Abed Y, Abdulla K, Tibbi AG, Marcus O, El Massri MR, Gerichter CB, Melnick JL (1984) Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 6: 2; 467–470

    Article  Google Scholar 

  22. Lepow ML, Warren RJ, Gray N, Ingram VG, Robbins FC (1961) Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 264: 1071–1078

    Article  PubMed  CAS  Google Scholar 

  23. McBean AM, Modlin JF (1987) Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 6: 881–887

    Article  PubMed  CAS  Google Scholar 

  24. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R, The Field Staff and Coordinating Committee (1988) Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Amer J Epidemiol 128: 615–628

    CAS  Google Scholar 

  25. Minor PD ,Dunn G (1988) The effect of sequences in the 5’ non-coding region on the replication of polioviruses in the human gut. J Gen Virol 69: 1091–1096

    Article  PubMed  CAS  Google Scholar 

  26. Modlin JF, Onorato IM, McBean AM, Albrecht P ,Thoms ML, Nerhood L, Bernier R (1990) The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine. AJDC 144: 480–484

    PubMed  CAS  Google Scholar 

  27. Murray MG, Kuhn RJ, Arita M, Kawamura N, Nomoto A, Wimmer E (1988) Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc Natl Acad Sci USA 85: 3203–3207

    Article  PubMed  CAS  Google Scholar 

  28. Ogra PL (1984) Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis 6: S361–368

    Article  PubMed  Google Scholar 

  29. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD (1991) Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164: 191–194

    Article  PubMed  CAS  Google Scholar 

  30. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH (1991) Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 163: 1–6

    Article  PubMed  CAS  Google Scholar 

  31. Pan American Health Organization (1986) Polio incidence rises in Brazil’s northeast. EPI News 8:4–5

    Google Scholar 

  32. Patriarca PA, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Rev Infect Dis 13:926–939

    Article  PubMed  CAS  Google Scholar 

  33. Raconiello VR (1988) Poliovirus neurovirulence. Adv Virus Res 34: 217–246

    Article  Google Scholar 

  34. Retrospective assessment of vaccination coverage among school-aged children -selected U.S. cities, 1991 MMWR 41(6): 103–107

    Google Scholar 

  35. Robertson SE, Drucker JA, Farbe-Teste B, D’Diaye M, Traverso HP, Rovira EZ, Sow A, Sy MTA, Diouf F. (1988) Clinical efficacy of a new ,enhanced-potency, inactivated poliovirus vaccine. The Lancet 1: 897–900

    Article  CAS  Google Scholar 

  36. Roivainen M, Hovi T (1987) Intestinal trypsin can significantly modify antigenic prop erties of polioviruses: Implications for the use of inactivated poliovirus vaccine. J Virol 61:3749–3753

    PubMed  CAS  Google Scholar 

  37. Roivainen M, Hovi T (1988) Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin. J Virol 62: 3536–3539

    PubMed  CAS  Google Scholar 

  38. Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ (1985) Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. AJDC 139: 977–980

    PubMed  CAS  Google Scholar 

  39. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14: 568–579

    Article  PubMed  CAS  Google Scholar 

  40. van Wezel AL, van Stenis G, Hannik CA (1978). New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Div Biol Stand 41: 159–168

    Google Scholar 

  41. von Magnus H, Petersen I (1984). Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 6: 471–474

    Article  Google Scholar 

  42. Westrop GD, Wareham KA, Evans DMA, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW (1989) Genetic basis for attenuation of the Sabin type 3 oral poliovirus vaccines. J Virol 63: 1338–1344

    PubMed  CAS  Google Scholar 

  43. Wright PF, Kim-Farley RJ ,de Quadros CA, Robertson SE, Scott RM, Ward NA, Henderson RH (1991) Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 325: 1772–1779

    Article  Google Scholar 

  44. Zhaori G, Sun M, Faden H, Ogra PL (1989) Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 159: 1018–1024

    Article  PubMed  CAS  Google Scholar 

  45. Zhaori G, Sun M, Ogra PL (1988) Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J Infect Dis 158: 160–165

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Pediatrics, State University of New York, School of Medicine at Buffalo and the Children’s Hospital of Buffalo, Buffalo, New York, USA

    H. Faden

Authors
  1. H. Faden
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, University of Montreal, Montreal, Canada

    Edouard Kurstak (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization) (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization)

  2. International Comparative Virology Organization, Montreal, Canada

    Edouard Kurstak (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization) (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization)

  3. Medical Research Centre, King Fahad Hospital, Riyadh, Saudi Arabia

    Edouard Kurstak (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization) (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization)

  4. Viral Diseases Panel, World Health Organization, Geneva, Switzerland

    Edouard Kurstak (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization) (President - International Comparative Virology Organization, Member - Viral Diseases Panel, World Health Organization)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag/Wien

About this chapter

Cite this chapter

Faden, H. (1993). Poliovirus combined immunization with inactivated and live attenuated vaccines. In: Kurstak, E. (eds) Measles and Poliomyelitis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9278-8_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9278-8_26

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82436-8

  • Online ISBN: 978-3-7091-9278-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation